Ondine Biomedical Inc. (OBI.L)
LSE · GBp · Healthcare · Biotechnology
£9.75 (+0.00%) as of
Key statistics
- Market cap
- 64.47M
- Forward P/E
- -6.96
- EPS (TTM)
- -0.03
- Dividend yield
- 0.00%
- 52-week range
- 0.10 – 15.50
- Beta
- 0.35
- Revenue (TTM)
- 2.88M
- Profit margin
- 0.00%
- Analyst target
- £29.00
- Volume
- 815.76k
About Ondine Biomedical Inc.
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-associated pneumonia, burns and other indications. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Vancouver, BC, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.